REG - Oxford Biomedica PLC - Total Voting Rights

Oxford BioMedicaAnnouncement

03/09/2018 09:20

RNS Number : 5453Z
Oxford Biomedica PLC
03 September 2018
 


 
 
 
 
 
 
Oxford BioMedica
Total Voting Rights
 
 
Oxford, UK - 3 September 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 31 August 2018 consisted of 66,039,775 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.
 
Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is 66,039,775.
 
The above figure (66,039,775) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.
 
- Ends -
 



For further information, please contact:


 




 
Oxford BioMedica plc:
John Dawson,  Chief Executive Officer
Stuart Paynter, Chief Financial Officer


 
Tel: +44 (0)1865 783 000




 
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/
Olivia Manser/Laura Thornton
 


 
 
Tel: +44 (0)20 3709 5700



 
Notes for editors
 
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVREAPNDEFPPEEF